[Effects of simvastatin therapy on the lipid blood spectrum and nitric oxide in patients with chronic glomerulonephritis].
The authors have evaluated the effects of Simvastatin on the lipid blood spectrum and nitric oxide in patients with chronic glomerulonephritis (CGN). 100 patients with different types of glomerular disease were divided in two groups depending on the treatment scheme: Group B received the traditional therapy, Group A patients received traditional therapy + 20 mg Simvastatin per day. Nitric oxide radicals, NADPF-diaphorase, nitrate reductase, acetylcholinesterase enzymes, as well as total cholesterol, triglycerides, HD, LD, VLD lipoproteins concentration were assessed initially and after three month treatment. It was revealed that the treatment with statins taking into account types of dislipidemia could have an additional renoprotective effect in the patients with different types of chronic glomerular disease.
Daminov
B T
BT
Raimkulova
N P
NP
D000328:Adult; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D005260:Female; D005921:Glomerulonephritis / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D050356:Lipid Metabolism / Q000187:drug effects; D008055:Lipids / Q000097:blood*; D008297:Male; D009569:Nitric Oxide / Q000097:blood* / Q000378:metabolism; D019821:Simvastatin / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D000960:Hypolipidemic Agents; D008055:Lipids; D009569:Nitric Oxide; D019821:Simvastatin